| Death rate of wild-type and mutant tumor cells due to chemotherapy |
| day−1 | [25] , [32] |
| Chemotherapy-induced death rate of wild-type and mutant tumors due to mAbs cetuximab and panitumumab |
| L mg−1 day−1 | [32] |
| Chemotherapy efficacy coefficient on wild-type and mutant cancer cells |
| L mg−1 | [32] |
Y | Determines the percent level of the maximum rate of mAb-induced tumor death of wild-type and mutant cells | 0.75 | unitless | [32] |
| Rate of mAb-induced wild-type and mutant tumor cell death |
for cetuximab
for panitumumab | L mg−1 day−1 | [32] |
f | Rate of NK cell turnover |
| day−1 | [32] |
e | Rate of NK synthesis from circulating lymphocytes |
| day−1 | [32] |
| IL-2 concentration needed for half-maximal NK cell proliferation |
| IU L−1 | [32] |
| Rate of IL-2-induced NK cell proliferation |
| day−1 | [32] |
p | Rate of NK cell death due to interaction with the tumor |
| cell−1 day−1 | [32] |
| Rate of NK cell death due to interaction with mAbs complexes |
(0 for panitumumab) | cell−1 day−1 | [32] |
| Rate of NK cell depletion due to chemotherapy toxicity |
| day−1 | [32] |
| Coefficient of chemotherapy toxicity on NK cells |
| L mg−1 | [32] |
m | Rate of turnover of activated CD8+ T cells |
| day−1 | [32] |
| IL-2 concentration required to halve the CD8+ T cell turnover rate |
| IU L−1 | [32] |
q | Rate of CD8+ T cell death due to interaction with the tumor |
| cell−1 day−1 | [32] |
| Rate of activation of CD8+ T cell due to NK cell-lysed tumor cell debris |
| cell−1 day−1 | [32] |
| Rate of CD8+ T cell production from circulating lymphocytes |
| cell−1 day−1 | [32] |